Cross-agency comparison: 🇪🇺 EMA leads with 91 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

This cross-agency pattern suggests that the EMA is currently the most active and potentially the most demanding environment for external regulatory monitoring, with MHRA and Health Canada also showing meaningful output that could signal steady procedural and guidance churn. By contrast, the FDA’s lower document count may indicate a comparatively quieter period across divisions, though sponsors should not equate fewer documents with lower complexity. For global filing strategy, this may suggest that companies should prioritize regulatory intelligence and dossier maintenance capacity around Europe first, then the UK and Canada, while still preserving sufficient U.S. bandwidth for division-specific changes that can emerge less visibly. Sponsors should consider building a more dynamic, region-weighted resourcing model, because the current output mix could favor earlier alignment to EMA-led expectations and more frequent cross-market harmonization work.